Loading...
Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion
Tisagenlecleucel demonstrated high rates of durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) in the JULIET trial. Most patients (92%) received bridging therapies to control disease after study entry and before tisagenlecleucel infusion. Here,...
Saved in:
| Published in: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society of Hematology
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6650727/ https://ncbi.nlm.nih.gov/pubmed/31332046 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000151 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|